Literature DB >> 11396138

Expression and possible role of cyclin D3 in human pancreatic adenocarcinoma.

Y Ito1, T Takeda, K Wakasa, M Tsujimoto, N Matsuura.   

Abstract

BACKGROUND: Cyclin D3, one of the D type cyclins, has been known as a cell cycle modulator at the G1-S phase. In the present study, we investigated its expression in pancreatic adenocarcinoma in order to elucidate its clinical role.
MATERIALS AND METHODS: We examined cyclin D3 as well as, cyclin D1 overexpression in 60 pancreatic adenocarcinoma by means of immunohistochemistry.
RESULTS: Cyclin D3 overexpression was found in 33.3% (20 cases) of the cases, being more frequently seen in cases showing high Ki-67 labeling index, stage IV, moderate- or poor-differentiation, lymph node metastasis and large size and cyclin D1 overexpression. Multivariate logistic analysis independently linked cyclin D3 overexpression to tumor size (p = 0.0392) and stage (p = 0.0312). Cyclin D1 overexpression was observed in 41.7% (25 cases) and was related to Ki-67 labeling index, cyclin A overexpression, stage, carcinoma differentiation, lymph node metastasis, tumor size, lymphatic invasion, perineural invasion and retropancreatic invasion. It was independently linked to carcinoma differentiation (p = 0.0081), lymph node metastasis (p = 0.0426) and lymphatic invasion (p = 0.0269).
CONCLUSION: These results suggest that cyclin D3, as well as cyclin D1, plays a role in the progression, including cell proliferating activity, of pancreatic adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11396138

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  Beta-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: relationships with carcinogenesis and metastasis.

Authors:  Yu-Jun Li; Zhi-Min Wei; Yun-Xiao Meng; Xiang-Rui Ji
Journal:  World J Gastroenterol       Date:  2005-04-14       Impact factor: 5.742

2.  Combined effect of cyclin D3 expression and abrogation of cyclin D1 prevent mouse skin tumor development.

Authors:  Xian Wang; Christopher Sistrunk; Paula L Miliani de Marval; Yongbaek Kim; Marcelo L Rodriguez-Puebla
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

3.  The molecular targets for the diagnosis and treatment of pancreatic cancer.

Authors:  Alexios S Strimpakos; Kostas N Syrigos; Muhammad Wasif Saif
Journal:  Gut Liver       Date:  2010-12-17       Impact factor: 4.519

4.  Nucleoporin levels regulate cell cycle progression and phase-specific gene expression.

Authors:  Papia Chakraborty; Yaming Wang; Jen-Hsuan Wei; Jan van Deursen; Hongtao Yu; Liviu Malureanu; Mary Dasso; Douglass J Forbes; David E Levy; Joachim Seemann; Beatriz M A Fontoura
Journal:  Dev Cell       Date:  2008-11       Impact factor: 12.270

5.  Cx31.1 acts as a tumour suppressor in non-small cell lung cancer (NSCLC) cell lines through inhibition of cell proliferation and metastasis.

Authors:  Deqiang Zhang; Chengwen Chen; Yuan Li; Xuping Fu; Yi Xie; Yao Li; Yan Huang
Journal:  J Cell Mol Med       Date:  2012-05       Impact factor: 5.310

6.  Cyclin D1 overexpression correlates with poor tumor differentiation and prognosis in gastric cancer.

Authors:  Yan-Shen Shan; Hui-Ping Hsu; Ming-Derg Lai; Yu-Hsuan Hung; Chih-Yang Wang; Meng-Chi Yen; Yi-Ling Chen
Journal:  Oncol Lett       Date:  2017-08-09       Impact factor: 2.967

7.  Cyclin D3 deficiency inhibits skin tumor development, but does not affect normal keratinocyte proliferation.

Authors:  Sung Hyun Lee; Xian Wang; Sun Hye Kim; Yongbaek Kim; Marcelo L Rodriguez-Puebla
Journal:  Oncol Lett       Date:  2017-07-08       Impact factor: 2.967

Review 8.  Prognostic significance of cyclin D3 expression in malignancy patients: a meta-analysis.

Authors:  Bo Wang; Zijian Wang; Lizhi Han; Song Gong; Yanxue Wang; Zhiwen He; Yong Feng; Zhaohui Yang
Journal:  Cancer Cell Int       Date:  2019-06-10       Impact factor: 5.722

9.  Expression of D-type cyclins in colon cancer and in cell lines from colon carcinomas.

Authors:  A Mermelshtein; A Gerson; S Walfisch; B Delgado; G Shechter-Maor; J Delgado; A Fich; L Gheber
Journal:  Br J Cancer       Date:  2005-08-08       Impact factor: 7.640

10.  Cell cycle regulation and anticancer drug discovery.

Authors:  Jingwen Bai; Yaochen Li; Guojun Zhang
Journal:  Cancer Biol Med       Date:  2017-11       Impact factor: 4.248

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.